Postprocedural cTnI elevation commonly occurs in patients with coronary heart disease (CAD) undergoing percutaneous coronary intervention (PCI) and may significantly relate to poor outcomes [2,3]. The gene discussed is TNNI3; the disease is coronary artery disorder.